Updated Jul 16, 2026
Robb Gary Charles has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.22M.

Gary Charles Robb is the Chief Business Officer at Corcept Therapeutics Inc, a pharmaceutical company focused on developing treatments for disorders related to cortisol. He has been involved in multiple SEC filings related to his role at the company.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-09 | CORT | CORCEPT THERAPEUTICS INC | G — Bona-fide gift | 600 | $0.00 | |
| 2026-06-03 | CORT | CORCEPT THERAPEUTICS INC | F — Tax withholding / forfeiture | 358 | $70.44 | $25K |
| 2026-06-03 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 776 | $0.00 | |
| 2026-06-03 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 776 | $70.44 | $55K |
| 2026-05-15 | CORT | CORCEPT THERAPEUTICS INC | G — Bona-fide gift | 1.0K | $0.00 | |
| 2026-05-15 | CORT | CORCEPT THERAPEUTICS INC | G — Bona-fide gift | 1.0K | $0.00 | |
| 2026-05-15 | CORT | CORCEPT THERAPEUTICS INC | G — Bona-fide gift | 5.3K | $0.00 | |
| 2026-03-05 | CORT | CORCEPT THERAPEUTICS INC | F — Tax withholding / forfeiture | 121 | $35.97 | $4K |
| 2026-03-05 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 499 | $0.00 | |
| 2026-03-05 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 499 | $35.97 | $18K |
| 2025-12-29 | CORT | CORCEPT THERAPEUTICS INC | F — Tax withholding / forfeiture | 80.3K | $83.59 | $6.71M |
| 2025-12-29 | CORT | CORCEPT THERAPEUTICS INC | M — Option exercise | 145.0K | $3.88 | $563K |
| 2025-12-04 | CORT | CORCEPT THERAPEUTICS INC | F — Tax withholding / forfeiture | 148 | $79.78 | $12K |
| 2025-12-04 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 224 | $0.00 | |
| 2025-12-04 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 224 | $79.78 | $18K |
| 2025-09-02 | CORT | CORCEPT THERAPEUTICS INC | F — Tax withholding / forfeiture | 256 | $71.38 | $18K |
| 2025-09-02 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 251 | $0.00 | |
| 2025-09-02 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 251 | $71.38 | $18K |
| 2025-08-22 | CORT | CORCEPT THERAPEUTICS INC | F — Tax withholding / forfeiture | 2.7K | $71.17 | $190K |
| 2025-08-22 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale | 2.3K | $71.27 | $166K |
Gary Charles Robb is the Chief Business Officer at Corcept Therapeutics Inc, a pharmaceutical company focused on developing treatments for disorders related to cortisol. He has been involved in multiple SEC filings related to his role at the company.…
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($1.22M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Robb Gary Charles profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.